Key Insights:
- Dr. George Dickstein discusses the benefits his practice has experienced since partnering with Gastro Health, an MSO. This includes access to advanced data analytics and AI tools, which have improved patient care and operational efficiency, notably in polyp detection and vaccine updates.
- The partnership has expanded the practice’s reach in clinical trials, providing patients access to experimental therapies locally. This collaboration has enabled the practice to partake in high-level medical research and offer cutting-edge treatments.
- While acknowledging the controversies surrounding private equity in healthcare, Dr. Dickstein argues that their experience with a private equity-backed MSO has been positive, improving care and expanding access. He warns against regulatory actions that could threaten the viability of such beneficial partnerships in healthcare.
Dr. Dickstein’s commentary in the Boston Herald emphasizes the significant positive impact that partnering with an MSO has had on his gastroenterology practice, from enhancing medical services to facilitating participation in clinical research. He advocates for the continued support of such partnerships in healthcare, cautioning against regulations that could hinder the growth and effectiveness of independent medical practices.